Association between Selected Polymorphisms rs12086634, rs846910, rs4844880, rs3753519 of 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD11B1) and the Presence of Insulin Resistance in the Polish Population of People Living in Upper Silesia
Abstract
:1. Introduction
2. Aim
- Are there any significant differences in the distribution of genotypes and alleles of selected polymorphisms of the 11β-hydroxysteroid dehydrogenase gene (rs12086634, rs846910, rs4844880, rs3753519) between subjects with and without insulin resistance?
- Are there any significant differences in the distribution of genotypes and alleles of selected polymorphisms of the 11β-hydroxysteroid dehydrogenase gene (rs12086634, rs846910, rs4844880, rs3753519) between male and female subjects with and without insulin resistance?
- Is there any association between the studied polymorphisms of the 11β-hydroxysteroid dehydrogenase (rs12086634, rs846910, rs4844880, rs3753519) and the HOMA-IR coefficient?
3. Patients and Methods
3.1. Patients
3.2. Ethical Approval
3.3. Methods
3.4. Statistical Analysis
4. Results
5. Discussion
6. Conclusions
- There were no statistically significant differences in the distribution of genotypes and alleles of the examined polymorphisms of the 11β-hydroxysteroid dehydrogenase type 1 gene between subjects with and without insulin resistance (determined using the HOMA-IR;
- There were no statistically significant differences in the distribution of genotypes and alleles of the studied polymorphisms of the 11β-hydroxysteroid dehydrogenase type 1 gene between men and women with and without insulin resistance (determined using the HOMA-IR;
- rs846910 and rs1208663 polymorphisms of the 11β-hydroxysteroid dehydrogenase type 1 gene in the examined subjects have a significant effect on the magnitude of the HOMA-IR insulin resistance index.
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Vidra, N.; Trias-Llimós, S.; Janssen, F. Impact of obesity on life expectancy among different European countries: Secondary analysis of population-level data over the 1975–2012 period. BMJ Open 2019, 9, e028086. [Google Scholar] [CrossRef] [Green Version]
- Devang, N.; Satyamoorthy, K.; Rai, P.S.; Nandini, M.; Rao, S.; Phani, N.M.; Adhikari, P. Association of HSD11B1 gene polymorphisms with type 2 diabetes and metabolic syndrome in South Indian population. Diabetes Res. Clin. Pr. 2017, 131, 142–148. [Google Scholar] [CrossRef] [PubMed]
- Mlinar, B.; Marc, J.; Jensterle, M.; Bokal, E.V.; Jerin, A.; Pfeifer, M. Expression of 11β-hydroxysteroid dehydrogenase type 1 in visceral and subcutaneous adipose tissues of patients with polycystic ovary syndrome is associated with adiposity. J. Steroid Biochem. Mol. Biol. 2011, 123, 127–132. [Google Scholar] [CrossRef]
- Malavasi, E.L.V.; Kelly, V.; Nath, N.; Gambineri, A.; Dakin, R.S.; Pagotto, U.; Pasquali, R.; Walker, B.R.; Chapman, K.E. Functional Effects of Polymorphisms in the Human Gene Encoding 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1): A Sequence Variant at the Translation Start of 11β-HSD1 Alters Enzyme Levels. Endocrinology 2010, 151, 195–202. [Google Scholar] [CrossRef] [Green Version]
- Quteineh, L.; Vandenberghe, F.; Morgui, N.S.; Delacrétaz, A.; Choong, E.; Gholam-Rezaee, M.; Magistretti, P.; Bondolfi, G.; Von Gunten, A.; Preisig, M.; et al. Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments. Pharm. Genom. 2015, 25, 246–258. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chapman, K.; Holmes, M.; Seckl, J. 11β-Hydroxysteroid Dehydrogenases: Intracellular Gate-Keepers of Tissue Glucocorticoid Action. Physiol. Rev. 2013, 93, 1139–1206. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arroyo-Johnson, C.; Mincey, K. Obesity Epidemiology Worldwide. Gastroenterol. Clin. North Am. 2016, 45, 571–579. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- NCD Risk Factor Collaboration. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: A pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet 2017, 390, 2627–2642. [Google Scholar] [CrossRef] [Green Version]
- Samuel, V.T.; Shulman, G.I. The pathogenesis of insulin resistance: Integrating signaling pathways and substrate flux. J. Clin. Investig. 2016, 126, 12–22. [Google Scholar] [CrossRef] [Green Version]
- Shulman, G.I. Ectopic Fat in Insulin Resistance, Dyslipidemia, and Cardiometabolic Disease. N. Engl. J. Med. 2014, 371, 1131–1141. [Google Scholar] [CrossRef]
- Semple, R.K.; Savage, D.B.; Cochran, E.K.; Gorden, P.; O’Rahilly, S. Genetic syndromes of severe insulin resistance. Endocr. Rev. 2011, 32, 498–514. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Scott, R.A.; Fall, T.; Pasko, D.; Barker, A.; Sharp, S.J.; Arriola, L.; Balkau, B.; Barricarte, A.; Barroso, I.; Boeing, H.; et al. Common Genetic Variants Highlight the Role of Insulin Resistance and Body Fat Distribution in Type 2 Diabetes, Independent of Obesity. Diabetes 2014, 63, 4378–4387. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dahlman, I.; Rydén, M.; Brodin, D.; Grallert, H.; Strawbridge, R.; Arner, P. Numerous Genes in Loci Associated With Body Fat Distribution Are Linked to Adipose Function. Diabetes 2016, 65, 433–437. [Google Scholar] [CrossRef] [Green Version]
- Walford, G.A.; Porneala, B.C.; Dauriz, M.; Vassy, J.L.; Cheng, S.; Rhee, E.P.; Wang, T.; Meigs, J.B.; Gerszten, R.E.; Florez, J.C. Metabolite Traits and Genetic Risk Provide Complementary Information for the Prediction of Future Type 2 Diabetes. Diabetes Care 2014, 37, 2508–2514. [Google Scholar] [CrossRef] [Green Version]
- Stančáková, A.; Laakso, M. Genetics of type 2 diabetes. Endocr. Dev. 2016, 31, 203–220. [Google Scholar]
- Ahmad, S.; Poveda, A.; Shungin, D.; Barroso, I.; Hallmans, G.; Renström, F.; Franks, P.W. Established BMI-associated genetic variants and their prospective associations with BMI and other cardiometabolic traits: The GLACIER Study. Int. J. Obes. 2016, 40, 1346–1352. [Google Scholar] [CrossRef]
- De Sá, D.S.F.; Schulz, A.; Streit, F.E.; Turner, J.D.; Oitzl, M.S.; Blumenthal, T.D.; Schachinger, H. Cortisol, but not intranasal insulin, affects the central processing of visual food cues. Psychoneuroendocrinology 2014, 50, 311–320. [Google Scholar] [CrossRef]
- Penz, M.; Stalder, T.; Miller, R.; Ludwig, V.M.; Kanthak, M.K.; Kirschbaum, C. Hair cortisol as a biological marker for burnout symptomatology. Psychoneuroendocrinology 2018, 87, 218–221. [Google Scholar] [CrossRef]
- Terao, M.; Itoi, S.; Matsumura, S.; Yang, L.; Murota, H.; Katayama, I. Local Glucocorticoid Activation by 11β-Hydroxysteroid Dehydrogenase 1 in Keratinocytes. Am. J. Pathol. 2016, 186, 1499–1510. [Google Scholar] [CrossRef] [Green Version]
- Stimson, R.H.; Walker, B.R. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Minerva Endocrinol. 2007, 32, 141–159. [Google Scholar]
- Michalaki, M.; Kyriazopoulou, V.; Antonacopoulou, A.; Koika, V.; Nikolaou, M.; Tsoukas, A.; Kalfarentzos, F.; Vagenakis, A.G.; Voukelatou, G.; Papavassiliou, A.G. The Expression of Omental 11β-HSD1 Is Not Increased in Severely Obese Women with Metabolic Syndrome. Obes. Facts 2012, 5, 104–111. [Google Scholar] [CrossRef] [PubMed]
- Tomlinson, J.; Walker, E.A.; Bujalska, I.J.; Draper, N.; Lavery, G.G.; Cooper, M.S.; Hewison, M.; Stewart, P.M. 11β-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response. Endocr. Rev. 2004, 25, 831–866. [Google Scholar] [CrossRef] [PubMed]
- Nair, S.; Lee, Y.H.; Lindsay, R.S.; Walker, B.R.; Tataranni, P.A.; Bogardus, C.; Baier, L.J.; Permana, P.A. 11?-Hydroxysteroid dehydrogenase Type 1: Genetic polymorphisms are associated with Type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle. Diabetology 2004, 47, 1088–1095. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gambineri, A.; Tomassoni, F.; Munarini, A.; Stimson, R.H.; Mioni, R.; Pagotto, U.; Chapman, K.E.; Andrew, R.; Mantovani, V.; Pasquali, R.; et al. A combination of polymorphisms in HSD11B1 associates with in vivo 11 -HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome. Eur. J. Endocrinol. 2011, 165, 283–292. [Google Scholar] [CrossRef] [Green Version]
- Moon, S.-S.; Lee, Y.-S.; Kim, J.-G.; Kim, S.-W.; Jeong, J.-Y.; Jeon, E.-J.; Seo, H.-A.; Kwak, S.H.; Park, K.S.; Lee, I.-K. Relationship of 11.BETA.-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase gene polymorphisms with metabolic syndrome and type 2 diabetes. Endocr. J. 2011, 58, 949–959. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gasparin, C.C.; Leite, N.; Tureck, L.V.; Souza, R.L.; Milano-Gai, G.E.; Silva, L.R.; Lopes, W.A.; Furtado-Alle, L. Effects of polymorphisms in APOB, APOE, HSD11β1, PLIN4, and ADIPOQ genes on lipid profile and anthropometric variables related to obesity in children and adolescents. Genet. Mol. Biol. 2018, 41, 735–741. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Farag, A.G.A.; Badr, E.A.; Eltorgoman, A.M.A.; Assar, M.F.; Elshafey, E.N.; Tayel, N.R.; Aboutaleb, H.E. Role of 11β HSD 1, rs12086634, and rs846910 single-nucleotide polymorphisms in metabolic-related skin diseases: A clinical, biochemical, and genetic study. Clin. Cosmet. Investig. Dermatol. 2019, ume 12, 91–102. [Google Scholar] [CrossRef] [Green Version]
- Alberts, P.; Engblom, L.; Edling, N.; Forsgren, M.; Klingström, G.; Larsson, C.; Rönquist-Nii, Y.; Öhman, B.; Abrahmsén, L. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetology 2002, 45, 1528–1532. [Google Scholar] [CrossRef] [Green Version]
- Berthiaume, M.; Laplante, M.; Festuccia, W.; Gélinas, Y.; Poulin, S.; LaLonde, J.; Joanisse, D.R.; Thieringer, R.; Deshaies, Y. Depot-Specific Modulation of Rat Intraabdominal Adipose Tissue Lipid Metabolism by Pharmacological Inhibition of 11β-Hydroxysteroid Dehydrogenase Type 1. Endocrinology 2007, 148, 2391–2397. [Google Scholar] [CrossRef] [PubMed]
- Bhat, B.G.; Hosea, N.; Fanjul, A.; Herrera, J.; Chapman, J.; Thalacker, F.; Stewart, P.M.; Rejto, P.A. Demonstration of Proof of Mechanism and Pharmacokinetics and Pharmacodynamic Relationship with 4′-Cyano-biphenyl-4-sulfonic Acid (6-Amino-pyridin-2-yl)-amide (PF-915275), an Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1, in Cynomolgus Monkeys. J. Pharmacol. Exp. Ther. 2007, 324, 299–305. [Google Scholar] [CrossRef]
All Groups | All Women | All Men | All Groups Insulin Resistance | All Group Non-Insulin Resistance Group | Women Insulin Resistance Group | Women Non-Insulin Resistance Group | Men Insulin Resistance Group | Men Non-Insulin Resistance Group | |
---|---|---|---|---|---|---|---|---|---|
N | 507 100% | 284 56% | 223 44% | 374 74% | 133 26% | 219 77% | 65 23% | 160 72% | 63 28% |
Age [year] | 52.6 ± 2.3 | 53 ± 2.9 | 53 ± 2.7 | 54.5 ± 3.1 | 52.2 ± 2.1 | 54.1 ± 2.9 | 53.1 ±2.4 | 54.4 ± 2.8 | 52.7 ± 2.3 |
Sex F/M | 284/223 | 284/0 | 223/0 | 167/213 | 56/71 | 167/0 | 56/0 | 0/213 | 0/71 |
BMI [kg/m2] | 26.7 ± 1.3 | 26.3 ± 1.2 | 26.6 ± 1.3 | 27.7 ± 2.3 | 25.9 ± 0.7 | 26.7 ± 1.3 | 25.8 ± 0.9 | 26.6 ± 1.3 | 26.0 ± 1.1 |
Waist [cm] | 94.0 ± 4.7 | 93.1 ± 3.4 | 95.7 ± 4.1 | 98.2 ± 4.7 | 92.1 ± 4.2 | 95.1 ± 4.4 | 90.4 ± 4.2 | 99.7 ± 4.0 | 94.6 ± 4.8 |
Hypertension present yes/no | 262/245 | 146/138 | 133/90 | 198/176 | 69/64 | 111/108 | 35/30 | 95/65 | 38/25 |
DM present yes/no | 52/455 | 40/244 | 12/211 | 29/345 | 23/110 | 22/197 | 18/47 | 7/153 | 5/58 |
eGFR [mL/min/1.73 m2] | 92 ± 31.2 | 91 ± 31.2 | 92 ± 31.2 | 90 ± 31.1 | 83 ± 30.4 | 92 ± 31.2 | 84 ± 30.5 | 91 ± 31.4 | 82 ± 30.5 |
TC [mmol/l] | 6.2 ± 2.0 | 6.2 ± 1.9 | 6.3 ± 2.0 | 6.4 ± 2.0 | 6.2 ± 1.9 | 6.3 ± 2.0 | 6.2 ± 1.8 | 6.4 ± 2.0 | 6.2 ± 1.9 |
HDLC [mmol/l] | 1.3 ± 0.4 | 1.4 ± 0.5 | 1.4 ± 0.5 | 1.4 ± 0.5 | 1.3 ± 0.4 | 1.3 ± 0.3 | 1.3 ± 0.4 | 1.3 ± 0.5 | 1.2 ± 0.4 |
LDLC [mmol/l] | 4.3 ± 0.7 | 4.1 ± 0.6 | 4.3 ± 0.09 | 4.2 ± 0.7 | 4.1 ± 0.7 | 4.3 ± 0.8 | 4.1 ± 0.8 | 4.4 ± 0.5 | 4.2 ± 0.6 |
TG [mmol/l] | 1.4 ± 0.7 | 1.4 ± 0.7 | 1.5 ± 0.6 | 1.5 ± 0.2 | 1.3 ± 0.4 | 1.4 ± 0.5 | 1.3 ±0.4 | 1.6 ± 0.7 | 1.4 ± 0.3 |
HOMA-IR | 2.7 ± 1.8 | 2.5 ± 2.7 | 2.7 ± 2.6 | 3.2 ± 0.8 | 1.1 ± 0.4 | 3.4 ± 0.5 | 1.1 ± 0.4 | 3.1 ± 0.4 | 1.8 ± 0.4 |
rs846910 | rs3753519 | rs4844880 | rs1208663 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
AA | AG | GG | CC | CT | TT | AA | AT | TT | TT | GT | GG | |
All groups N/% | 1/0.20 | 46/9.07 | 460/90.73 | 380/74.95 | 110/21.69 | 17/3.36 | 38/7.5 | 138/27.21 | 331/65.29 | 347/68.45 | 137/27.02 | 23/4.53 |
All groups IR N/% | 1/0.25 | 37/9.46 | 354/90.28 | 277/75.27 | 82/21.19 | 13/3.54 | 30/8.15 | 101/26.57 | 249/65.52 | 259/66.66 | 94/28.87 | 17/4.47 |
All groups non-IR N/% | 0/0 | 9/7.82 | 106/92.18 | 103/76.97 | 28/20.14 | 4/2.89 | 8/6.30 | 37/29.13 | 82/64.57 | 88/61.11 | 43/34.12 | 6/4.77 |
All women | 0/0 | 24/8.46 | 260/91.54 | 217/72.98 | 58/23.58 | 9/3.44 | 20/7.04 | 78/27.46 | 186/65.5 | 190/65.56 | 79/28.93 | 15/5.49 |
All men N/% | 1/0.45 | 22/9.87 | 200/89.68 | 163/77.18 | 52/19.77 | 8/3.05 | 18/8.08 | 60/26.90 | 145/65.02 | 157/64.95 | 58/31.64 | 8/3.41 |
Women—IR N/% | 0/0 | 18/7.86 | 211/92.13 | 159/76.07 | 43/20.57 | 7/3.36 | 16/7.30 | 58/28.48 | 145/64.22 | 139/64.61 | 58/30.46 | 12/4.93 |
Women—non-IR N/% | 0/0 | 6/11.32 | 47/88.68 | 58/77.33 | 15/20.00 | 2/2.67 | 4/6.15 | 20/30.70 | 41/63.15 | 51/68.92 | 21/27.16 | 3/3.92 |
Men—IR N/% | 1/0.62 | 16/10.0 | 143/89.38 | 114/77.38 | 39/19.59 | 6/3.03 | 14/13.20 | 43/40.57 | 104/46.23 | 120/65.18 | 36/30.32 | 5/4.50 |
Men—non- IR N/% | 0/0 | 6/13.84 | 59/86.16 | 49/76.56 | 13/20.31 | 2/3.13 | 4/6.45 | 17/27.42 | 41/66.13 | 37/68.41 | 22/27.39 | 3/4.20 |
rs846910 | rs3753519 | rs4844880 | rs1208663 | |||||
---|---|---|---|---|---|---|---|---|
A | G | C | T | A | T | T | G | |
All groups N/% | 47/4.73 | 966/95.27 | 870/85.80 | 144/14.20 | 214/21.10 | 800/78.90 | 831/81.95 | 183/18.05 |
All groups—insulin resistance N/% | 38/4.86 | 745/95.14 | 636/85.86 | 108/14.14 | 161/21.18 | 599/78.82 | 612/82.70 | 128/17.30 |
All goups–non-insulin resistance N/% | 9/3.91 | 221/96.01 | 234/86.67 | 36/13.33 | 53/20.86 | 201/79.14 | 219/79.92 | 55/20.08 |
All women N% | 24/4.18 | 544/95.82 | 492/86.62 | 76/13.38 | 118/20.71 | 450/79.29 | 459/80.80 | 109/19.20 |
All men N/% | 23/5.02 | 422/94.98 | 378/84.76 | 68/15.24 | 96/21.52 | 350/78.48 | 372/83.40 | 74/16.60 |
Women—IR N/% | 18/3.90 | 440/96.10 | 361/71.92 | 141/28.08 | 90/21.62 | 348/78.37 | 336/80.38 | 82/19.62 |
Women—non-IR N/% | 6/5.45 | 100/94.55 | 131/87.33 | 19/12.66 | 28/21.53 | 102/78.46 | 123/82.00 | 27/18.00 |
Men—IR N/% | 17/6.30 | 302/93.70 | 267/87.18 | 51/12.81 | 71/22.19 | 251/77.81 | 276/85.71 | 46/14.28 |
Men—non-IR N/% | 6/4.68 | 124/95.32 | 111/86.71 | 17/13.28 | 25/20.16 | 99/79.82 | 96/77.41 | 28/22.58 |
rs846910 | rs3753519 | rs4844880 | rs1208663 | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AA | AG | GG | ANOVA | CC | CT | TT | ANOVA | AA | AT | TT | ANOVA | TT | GT | GG | ANOVA | |
All groups | 2.25 NA | 2.66 ± 1.5 | 2.66 ± 1.5 | NS | 2.77 ± 0.11 | 2.65 ± 2.02 | 2.92 ± 1.62 | NS | 2.75 ± 1.48 | 2.77 ± 2.45 | 2.74 ± 1.98 | NS | 2.67 ± 1.63 | 2.82 ± 2.7 | 3.5 ± 3.16 | p = 0.042 |
All groups—insulin resistance | 2.2 NA | 2.7 ± 1.3 | 2.8 ± 2.2 | p = 0.049 | 3.3 ± 2.2 | 3.2 ± 2.0 | 3.4 ± 1.5 | NS | 3.2 ± 1.3 | 3.3 ± 2.6 | 3.3 ± 2.0 | NS | 3.2 ± 1.6 | 3.5 ± 2.9 | 4.5 ± 3.3 | p < 0.049 |
All groups—non-insulin resistance | 0 NA | 1.06 ± 0.4 | 1.12 ± 0.3 | p = 0.038 | 1.13 ± 0.3 | 1.02 ± 0.3 | 1.2 ± 0,1 | NS | 1.06 ± 0.4 | 1.09 ± 0.6 | 1.13 ± 0.3 | p = 0.076 | 1.13 ± 0.3 | 1.1 ± 0,3 | 0.97 ± 0.3 | p = 0.047 |
All—women | 0 NA | 2.88 ± 0.88 | 2.9 ± 0.37 | p = 0.048 | 2.99 ± 0.51 | 2.46 ± 0.43 | 3.24 ± 0.9 | p = 0.048 | 2.98 ± 0.56 | 2.77 ± 0.62 | 2.93 ± 0.28 | NS | 1.52 ± 0.98 | 2.97 ± 0.95 | 3.91 ± 3.7 | p = 0.034 |
All—men | 2.25 NA | 2.42 ± 0.91 | 2.59 ± 1.81 | p = 0.049 | 2.46 ± 1.43 | 2.85 ± 2.51 | 2.55 ± 1.25 | p = 0.049 | 2.45 ± 1.36 | 2.76 ± 2.27 | 2.47 ± 1.42 | NS | 1.15 ± 0.76 | 2.8 ± 2.32 | 2.72 ± 1.69 | p = 0.044 |
Women—IR | 0 NA | 3.56 ± 1.7 | 3.44 ± 1.4 | p = 0.049 | 3.53 ± 2.6 | 3.06 ± 1.2 | 4.14 ± 1.7 | p = 0.049 | 3.51 ± 1.4 | 3.41 ± 2.7 | 3.47 ± 2.3 | p = 0.047 | 1.4 ± 1.4 | 3.59 ± 3.1 | 4.69 ± 3.7 | p = 0.023 |
Women—non-IR | 0 NA | 0.84 ± 0.3 | 1.03 ± 0.3 | NS | 1.03 ± 0.3 | 0.9 ± 0.3 | 1.3 ± 0.9 | NS | 1.11 ± 0.2 | 0.93 ± 0.3 | 1.04 ± 0.3 | NS | 0.12 ± 0.4 | 0.97 ± 0.4 | 0.81 ± 0.2 | p = 0.047 |
Men—IR | 2.25 NA | 2.65 ± 0.2 | 3.2 ± 0.9 | p = 0.049 | 3.04 ± 1.4 | 3.43 ± 1.7 | 2.96 ± 1.1 | p = 0.038 | 2.87 ± 1.2 | 3.28 ± 1.4 | 3.08 ± 1.4 | p = 0.017 | 3.03 ± 1 | 3.33 ± 1.6 | 3.67 ± 1.4 | p = 0.027 |
Men—non- IR | 0 NA | 1.39 ± 0.22 | 1.2 ± 0.31 | NS | 1.22 ± 0.3 | 1.17 ± 0.4 | 1.27 ± 0.2 | p = 0.049 | 1 ± 0.5 | 1.25 ± 0.3 | 1.22 ± 0.3 | NS | 2.22 ± 0.3 | 1.23 ± 0.3 | 1.12 ± 0.3 | p = 0.029 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Szweda-Gandor, N.; Śnit, M.; Grzeszczak, W. Association between Selected Polymorphisms rs12086634, rs846910, rs4844880, rs3753519 of 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD11B1) and the Presence of Insulin Resistance in the Polish Population of People Living in Upper Silesia. Int. J. Environ. Res. Public Health 2021, 18, 10168. https://doi.org/10.3390/ijerph181910168
Szweda-Gandor N, Śnit M, Grzeszczak W. Association between Selected Polymorphisms rs12086634, rs846910, rs4844880, rs3753519 of 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD11B1) and the Presence of Insulin Resistance in the Polish Population of People Living in Upper Silesia. International Journal of Environmental Research and Public Health. 2021; 18(19):10168. https://doi.org/10.3390/ijerph181910168
Chicago/Turabian StyleSzweda-Gandor, Nikola, Mirosław Śnit, and Władysław Grzeszczak. 2021. "Association between Selected Polymorphisms rs12086634, rs846910, rs4844880, rs3753519 of 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD11B1) and the Presence of Insulin Resistance in the Polish Population of People Living in Upper Silesia" International Journal of Environmental Research and Public Health 18, no. 19: 10168. https://doi.org/10.3390/ijerph181910168